Revolutionizing Mucosal Drug Delivery for Cardiopulmonary Applications
Pulmonary Arterial Hypertension (PAH) Treatments are lacking
Pulmonary Arterial Hypertension (PAH) is a life-threatening cardiovascular disease that has poor long-term outcomes due to limited, high burden treatment options.
Existing therapies suffer from low bioavailability due to a very short plasma half-life
Inhaled therapies require 6-9 doses per day, usually administered in a clinical setting
IV administration requires continuous infusion, can have serious side effects, and presents infection risk
Confusing and tedious dosing schedule, especially among elderly and comorbid patients
The results in poor adherence to treatment - as low as ~22.6% at one year for iloprost
MUCOSAL DRUG DELIVERY CAN IMPROVE THESE TREATMENT OPTIONS & OUTCOMES
Unlocking the Growing Inhaled PAH Market Opportunity
*Global Data, 2025
ANNUAL TREATMENT COSTS FOR PATIENTS ON INHALED THERAPIES ARE ESTIMATED TO BE OVER $250,000
Mucosal Barriers Were Made to Keep Things Out - Including Therapeutics
Local treatments exist but they're often inefficient. Systemic treatments risk high off-target exposure to compensate for the poor uptake. The result? More side effects, higher dosing burden and less relief for patients.
It doesn’t have to be this way. Our approach delivers drugs directly to mucosal surfaces and keeps them there without relying on high doses or systemic exposure
WHAT ONCE KEPT THERAPIES OUT NOW HELPS BRING DRUGS IN - PRECISELY WHERE THEY’RE NEEDED
OptimEyes’ Mucoadhesive Nanoparticles (MNP) Technology Platform
Our MNPs are a proprietary next generation drug delivery platform that maximizes the efficacy of new and existing APIs to improve patients’ lives
MNPs PROVIDE A PROTECTIVE MICELLE ENVIRONMENT THAT ENHANCES DRUG SOLUBILITY, STABILITY AND ABSORPTION AT THE BODY’S MUCOSAL BARRIERS
MNPs Enable Mucoadhesive, Sustained Drug Delivery that Improves Outcomes
OptimEyes’ MNP platform represents a paradigm shift in mucosal drug delivery
BY WORKING WITH THE MUCOSAL BARRIER, WE ENABLE BETTER LOCAL ABSORPTION, FEWER SIDE EFFECTS AND SIMPLER, MORE EFFECTIVE TREATMENT FOR PATIENTS
MNPs Have a Clear Advantage in PAH’s Competitive Landscape
MNPs ENABLE ENHANCED DRUG LOADING AND SUSTAINED RELEASE FOR MANY APIs, TURNING NOVEL API COMPETITORS INTO POTENTIAL PARTNERS
Pursuing a De-Risked Regulatory & Accelerated Go-to-Market Strategy that Fits with PAH
Key Milestone for OPT-401 Development
Redefining PAH Therapy with MNPs: Delivering a Step-Change for Patients
Combining our mucoadhesive nanoparticle platform with iloprost transforms PAH treatments. It provides patients with an easier treatment that is more effective and has fewer side effects.
We are not just improving delivery- we’re transforming the therapeutic experience for patients, caregivers and providers.
OUR APPROACH UNLOCKS A 505 (B)(2) REGULATORY PATHWAY TO A $9B+ MARKET FOR QUICK CLINICAL AND COMMERCIAL ACCESS, ALIGNING WITH PAYER AND PROVIDER INCENTIVES TO PROVIDE A COST-EFFECTIVE, PATIENT-FRIENDLY SOLUTION. WE ARE POSITIONED TO DELIVER A STEP-CHANGE INNOVATION WITH SIGNIFICANT COMMERCIAL AND CLINICAL UPSIDE